Purple Biotech (PPBT) Stock: Buy, Sell, or Hold?
PPBT - Purple Biotech Ltd. American Depositary Shares
$1.05
-0.10 (-8.70%)
▼
5d:
-14.63%
30d:
-29.29%
90d:
-26.57%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 13, 2026
20d
Get Alerted When PPBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PPBT is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PPBT is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PPBT is currently trading at $1.05, which is considered oversold relative to its 30-day fair value range of $1.23 to $1.59.
Technical Outlook: Technically, PPBT is in a downtrend. The price is currently testing key support at $1.05. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.7% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.00 (+1519.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PPBT is in a downtrend. The price is currently testing key support at $1.05. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.7% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.00 (+1519.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.23 -
$1.59
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.7%)
- BULLISH: Trading 1519.0% below Wall St target ($17.00)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.23 -
$1.59
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.05
Resistance Level
$1.44
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.04
Wall Street Target
$17.00
(+1519.0%)
Share & Embed Analysis
Last updated: October 23, 2026 3:46 AM ET
Data refreshes hourly during market hours. Next update: 4:46 AM
Data refreshes hourly during market hours. Next update: 4:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PPBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 56 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TRVI
Trevi Therapeutics Inc |
STRONG BUY
11 analysts |
$28 | 69 BUY |
